Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.54 -0.89 (-1.50%)
Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
88 89 Next >
News headline image
S&P 500 Rallies 2% On Nvidia, Tesla Gains — But Market Mood Stuck In 'Fear' ↗
 
Via Benzinga
Topics Stocks
News headline image
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results ↗
 
Via Benzinga
News headline image
Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact ↗
Bristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy product declines. 
Via Benzinga
News headline image
Bristol Myers Reports Upbeat Q1 Earnings, Raises Full-Year Guidance: Retail’s Optimistic ↗
The company now expects full-year diluted EPS in the range of $6.70 to $7.00, up from its previous guidance of $6.55 to $6.85. 
Via Stocktwits
Topics World Trade
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday? ↗
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
News headline image
Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates ↗
The company recently faced two big clinical trial setbacks that have weighed on shares recently. 
Via Investor's Business Daily
Topics Government
News headline image
Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 5.6% year on year to $11.2 billion. The company’s... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
US Stock Futures Drop Amid Mixed Signals From White House On US-China Trade: 'Focus On Quality In A Diversified Manner,' Says Expert ↗
U.S. stock futures fell on Thursday after a two-day advance. Futures of major benchmark indices were lower in premarket. 
Via Benzinga
News headline image
PepsiCo, Alphabet And 3 Stocks To Watch Heading Into Thursday ↗
 
Via Benzinga
News headline image
Dow Jumps Over 400 Points Amid China Tariff Hopes, Investor Fear Eases: Greed Index Remains In 'Fear' Zone ↗
 
Via Benzinga
Topics Stocks
News headline image
Stay informed with the top movers within the S&P500 index on Wednesday. ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
What's going on in today's pre-market session: S&P500 movers ↗
Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides ↗
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
News headline image
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
News headline image
Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The Dip ↗
A post-hoc analysis showed more pronounced effects among patients on risperidone compared to those on other antipsychotics, the company said. 
Via Stocktwits
Topics Intellectual Property
News headline image
Stay updated with the S&P500 stocks that are on the move in today's after-hours session. ↗
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock ↗
 
Via Benzinga
News headline image
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test ↗
The company spent $14 billion to acquire the developer of this drug, Cobenfy. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach ↗
FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
From Bristol Myers Squibb
Via Business Wire
News headline image
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
News headline image
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? ↗
Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Tuesday? ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.